SCHEMBL3199570

SCHEMBL3199570

COc1ccc(OC(=O)[C@H](C)N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.48
CA1 P00915 5/20 0.48
CA2 P00918 5/20 0.48
PARP10 Q53GL7 2/20 0.48
PARP1 P09874 1/20 0.48
PARP2 Q9UGN5 1/20 0.48
PARP4 Q9UKK3 1/20 0.48
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
TAS1R2 Q8TE23 1/20 0.46
SLC6A4 P31645 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
LMNA P02545 1/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15679080 0.92 ELANE (0.55) ELANEPARP10CYP1A2CYP2C9CYP2C19
SCHEMBL23493150 0.92 ELANE (0.55) ELANEPARP10CYP1A2CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL30184762 0.90 ELANE (0.53) ELANEPARP10CYP1A2CYP2C9CYP2C19
SCHEMBL28774781 0.85 ELANE (0.46) ELANECA1CA2PARP10PARP1
SCHEMBL28774783 0.85 ELANE (0.46) ELANECA1CA2PARP10PARP1
SCHEMBL15679089 0.84 ELANE (0.48) ELANECA1CA2PARP10CA12
SCHEMBL2402636 0.84 ELANE (0.48) ELANECA1CA2PARP10CA12
SCHEMBL5058438 0.84 LMNA (0.55) ELANECYP1A2CYP2C9CYP2C19LMNA
SCHEMBL239299 0.84 ELANE (0.48) ELANEPARP10CYP1A2CYP2C9CYP2C19
SCHEMBL12616903 0.83 ELANE (0.68) ELANECA1CA2PARP10PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0950046-B1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS NAEJA PHARMACEUTICAL INC (CA) 2002-04-10 EP claimed
CN-1112125-A Acyloxyhexanoic acid derivatives CIBA GEIGY AG (CH) 1995-11-22 CN claimed
EP-0320204-A2 Renin inhibiting dipeptides, their preparation and compositions containing them GLAXO GROUP LIMITED (GB) 1989-06-14 EP claimed
EP-0320205-A2 Renin inhibiting dipeptides, their preparation and compositions containing them GLAXO GROUP LIMITED (GB) 1989-06-14 EP claimed
US-20230365646-A1 AZIDE INSULIN ANALOGUES MERCK SHARP & DOHME LLC (US) 2023-11-16 US disclosed
US-20210163568-A1 AZIDE INSULIN ANALOGUES MERCK SHARP & DOHME CORP. (US) 2021-06-03 US disclosed
EP-3773683-A1 AZIDE INSULIN ANALOGUES Merck Sharp&Dohme Corp. (US) 2021-02-17 EP disclosed
EP-3270977-B1 OPTICAL PROBES FOR MATRIX METALLOPROTEINASES UNIV COURT UNIV OF EDINBURGH (GB) 2020-06-17 EP disclosed
EP-3661955-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES Synthorx, Inc. (US) 2020-06-10 EP disclosed
WO-2019199628-A1 AZIDE INSULIN ANALOGUES MERCK SHARP & DOHME CORP. (US) 2019-10-17 WO disclosed
WO-2019028425-A1 CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES Synthorx, Inc. (US) 2019-02-07 WO disclosed
CN-104387372-B Oxo azetidine derivatives, preparation method and its purposes in human medical and cosmetics 盖尔德马研究及发展公司 2018-06-26 CN disclosed
EP-1679302-A1 AROMATIC AMINO ACID LABELED WITH STABLE ISOTOPE, METHOD FOR INCORPORATING THE SAME INTO TARGET PROTEIN AND METHOD FOR ANALYZING PROTEIN STRUCTURE USING NMR Japan Science and Technology Agency (JP) 2006-07-12 EP disclosed
WO-2006009623-A1 DETECTION OF PROTEIN EXPRESSION IN VIVO USING FLUORESCENT PUROMYCIN CONJUGATES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2006-01-26 WO disclosed
CN-1142492-A Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents PFIZER (US) 1997-02-12 CN disclosed
CN-1112125-A Acyloxyhexanoic acid derivatives CIBA GEIGY AG (CH) 1995-11-22 CN disclosed
EP-0320204-A3 RENIN INHIBITING DIPEPTIDES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 1991-07-24 EP disclosed
EP-0320205-A3 RENIN INHIBITING DIPEPTIDES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 1991-07-24 EP disclosed
EP-0320204-A2 Renin inhibiting dipeptides, their preparation and compositions containing them GLAXO GROUP LIMITED (GB) 1989-06-14 EP disclosed
EP-0320205-A2 Renin inhibiting dipeptides, their preparation and compositions containing them GLAXO GROUP LIMITED (GB) 1989-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163568-A1 AZIDE INSULIN ANALOGUES IAPP, INSR, GPR119 ELANE 2441/4885CA1 3176/4885CA2 3451/4885
US-20230365646-A1 AZIDE INSULIN ANALOGUES IAPP, INSR, GPR119 ELANE 2441/4885CA1 3176/4885CA2 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.